Study: NCT03984812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3732394
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.